July 13, 2014 4:25 AM ET

Healthcare Equipment and Supplies

Company Overview of Ocular Therapeutix, Inc.

Company Overview

Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company’s earlier stage product candidat...

36 Crosby Drive

Suite 101

Bedford, MA 01730

United States

Founded in 2006

54 Employees

Phone:

781-357-4000

Fax:

781-357-4001

Key Executives for Ocular Therapeutix, Inc.

Founder
Age: 47
Chief Financial Officer and Principal Accounting Officer
Age: 58
Chief Operating Officer
Executive Vice President of Clinical
General Manager
Compensation as of Fiscal Year 2014.

Ocular Therapeutix, Inc. Key Developments

Ocular Therapeutix Seeks Acquisitions

Ocular Therapeutix, Inc. has filed an IPO in the amount of $86.25 million. Ocular Therapeutix will use the net proceeds from this offering to fund the clinical development of most advanced product candidates, OTX-DP and OTX-TP, and for working capital and other general corporate purposes, including expansion of our manufacturing capacity, sales and marketing activities, development of preclinical product candidates and pursuit of other research and development efforts.

Ocular Therapeutix to Present New Data on Sustained Release Drug Candidates Utilizing Proprietary Hydrogel Technology at the Association for Research in Vision and Ophthalmology Annual Meeting

Ocular Therapeutix to present new data on sustained release drug candidates utilizing Proprietary Hydrogel Technology at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting April 28, 2014. The company announced six posters will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in taking place at the Orange County Convention Center in Orlando, Florida, from May 4-8, 2014. Details of the poster presentations at the ARVO Annual Meeting: May 4, 2014: Exhibit/Poster Hall SA: In Vivo Drug Delivery of Low Solubility Drugs from Biodegradable Hydrogel Punctum Plugs. Authors: Michael McGrath; Charles D. Blizzard; Ankita Desai; Michael Bassett; Peter Jarrett, Ph.D.; Arthur Driscoll; Amarpreet Sawhney, Ph.D. Session: Drug Delivery #1 | 8:30-10:15AM; in Vitro/In Vivo Correlation of Travoprost Release from a Biodegradable Hydrogel Punctum Plug for the Treatment of Glaucoma. Authors: Monica O’Connor; Charles D. Blizzard; Michael Bassett; Ankita Desai; Steve Takach; Doug Molla; Bill Cowe; Jennifer Wittbold; Arthur Driscoll; Amarpreet Sawhney, Ph.D. Session: Drug Delivery #1 | 8:30-10:15AM. May 5, 2014: Exhibit/Poster Hall SA; and Pharmacodynamics of Dexamethasone Delivery from a Punctum Plug in Cataract Patients. Authors: Michael Bassett; Samuel Masket, MD; Thomas D. Walters, MD; Michael Endl, MD; Jeffery Levenson, MD; Parag Majmudar, MD; Deepa Mulani; Stephen Curwen; Charles D. Blizzard; Amarpreet Sawhney Ph.D. Session: Cataract Surgery 1 | 3:45-5:30PM. May 7, 2014: Exhibit/Poster Hall SA: Safety of the Dexamethasone Punctum Plug is Demonstrated in a Canine Toxicity Study. Authors: Charles D. Blizzard; Ankita Desai; Amarpreet Sawhney, Ph.D.; Michael McGrath; Peter Jarrett; Arthur Driscoll; Bill Cowe; Doug Molla; Monica O’Connor; Jennifer Wittbold. Session: Ocular Toxicity/Toxicology | 11:00AM- 12:45PM; 90-Day Canine Toxicity Study Demonstrating the Safety of a Sustained Release Travoprost Punctum Plug. Authors: Monica O’Connor; Charles D. Blizzard; Michael Bassett; Steve Takach; Doug Molla; Arthur Driscoll; Amarpreet Sawhney, Ph.D.; Peter K. Jarrett, PhD. Session: Ocular Toxicity/Toxicology | 11:00AM- 12:45PM; and Sustained Release of Bevacizumab from Hydrogel Depots for Intravitreal Injections. Authors: Rami F. El-Hayek, Ph.D.; Amarpreet Sawhney, Ph.D.; Peter Jarrett, Ph.D.; Sarah Guedez, Courtney Rosales. Session: Drug Delivery #2 | 3:45-5:30PM.

Ocular Therapeutix, Inc. Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone

Ocular Therapeutix, Inc. announced the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days. In the first of two prospective, multicenter, randomized, parallel-arm, double-masked, vehicle-controlled studies, 240 patients undergoing clear corneal cataract surgery will be enrolled at sites throughout the United States. Following surgery, patients will be randomized to either the dexamethasone treatment group or a placebo vehicle plug. Primary endpoints are absence of anterior chamber cells at day 14 and reduction of pain at day 8. Physicians routinely prescribe topical steroids post-operatively for the treatment of ocular inflammation and pain. However, patients do not reliably self-administer these drops, which could lead to greater or more persistent inflammation and subsequently affect visual outcomes. Conversely, chronic use of topical steroids can lead to elevations in intraocular pressure, which is a risk factor for glaucoma.

Similar Private Companies By Industry

Company Name Region
Inspire Medical Systems, Inc. United States
Solvonics LLC United States
Ardiem Medical, Inc. United States
J.T. Posey Company, Inc. United States
TECHLAB, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ocular Therapeutix, Inc., please visit www.ocutx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.